SCHEMBL2857356

SCHEMBL2857356

Cn1c(N)nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.49
PTPN1 P18031 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
CCNT1 O60563 2/20 0.40
CDK9 P50750 2/20 0.40
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
CLK4 Q9HAZ1 2/20 0.39
NTRK1 P04629 1/20 0.39
LTK P29376 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23679807 0.79 SMN1; SMN2 (0.55) PTPN1ALOX15HTTCCNT1CDK9
SCHEMBL4882909 0.78 KDM4E (0.58) PTPN1ALOX15HTTCCNT1CDK9
SCHEMBL1977970 0.77 BACE1 (0.56) PRMT5KDM4EKMT2ANPC1ALDH1A1
SCHEMBL12598297 0.77 ADORA3 (0.47) PRMT5PTPN1KDM4EKMT2AMEN1
SCHEMBL30621926 0.77 ADORA3 (0.47) PRMT5PTPN1KDM4EKMT2AMEN1
SCHEMBL3991199 0.76 PTPN1 (0.41) PTPN1ALOX15HTTCCNT1CDK9
SCHEMBL7783106 0.76 HTT (0.68) PTPN1ALOX15HTTCCNT1CDK9
SCHEMBL18965901 0.76 KDM4E (0.43) PRMT5ALOX15HTTKDM4EKMT2A
SCHEMBL2734327 0.76 KDM4E (0.52) PRMT5ALOX15HTTKDM4EKMT2A
SCHEMBL12827024 0.76 PTPN1 (0.41) PTPN1ALOX15HTTCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 PRMT5 2030/4885PTPN1 1455/4885ALOX15 1764/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 PRMT5 2030/4885PTPN1 1455/4885ALOX15 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.